Propel Bio Management as of Dec. 31, 2025
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 20 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Plains Gp Hldgs Ltd Partnr Int A (PAGP) | 20.8 | $24M | 1.3M | 19.14 | |
| Achieve Life Sciences (ACHV) | 16.1 | $19M | 3.8M | 4.97 | |
| Phathom Pharmaceuticals (PHAT) | 10.5 | $12M | 741k | 16.59 | |
| Miragen Therapeutics (VRDN) | 7.5 | $8.8M | 283k | 31.12 | |
| Milestone Pharmaceuticals (MIST) | 7.1 | $8.3M | 4.1M | 2.02 | |
| Kyverna Therapeutics (KYTX) | 5.4 | $6.3M | 667k | 9.40 | |
| Compass Pathways Sponsored Ads (CMPS) | 5.1 | $5.9M | 862k | 6.90 | |
| Inventiva Sa - Ads (IVA) | 4.0 | $4.7M | 1.0M | 4.65 | |
| Delcath Systems Com New (DCTH) | 3.8 | $4.4M | 439k | 10.10 | |
| Abeona Therapeutics Com New (ABEO) | 3.7 | $4.4M | 831k | 5.27 | |
| Celldex Therapeutics Com New (CLDX) | 3.6 | $4.2M | 154k | 27.16 | |
| Nektar Therapeutics Com New (NKTR) | 3.0 | $3.5M | 83k | 42.28 | |
| Oculis Holding Ordinary Shares (OCS) | 2.9 | $3.5M | 173k | 19.97 | |
| Sab Biotherapeutics Com New (SABS) | 2.1 | $2.4M | 653k | 3.74 | |
| Regenxbio Inc equity us cm (RGNX) | 1.4 | $1.7M | 117k | 14.40 | |
| Athira Pharma | 1.0 | $1.1M | 149k | 7.57 | |
| Lenz Therapeutics (LENZ) | 0.8 | $945k | 59k | 16.00 | |
| Aardvark Therapeutics (AARD) | 0.5 | $609k | 46k | 13.12 | |
| Zevra Therapeutics Com New (ZVRA) | 0.5 | $571k | 64k | 8.96 | |
| Kalaris Therapeutics (KLRS) | 0.3 | $355k | 42k | 8.44 |
